Wells Fargo
ENGN icon

Wells Fargo’s enGene Therapeutics ENGN Stock Holding History

Wells Fargo’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.9K Buy
12,467
+1,250
+11% +$11.1K ﹤0.01% 5188
2025
Q4 		$101K Sell
11,217
-6,693
-37% -$53.6K ﹤0.01% 5381
2025
Q3 		$122K Buy
17,910
+14,711
+460% +$67.1K ﹤0.01% 5214
2025
Q2 		$11.6K Buy
3,199
+1,278
+67% +$4.79K ﹤0.01% 5913
2025
Q1 		$8.61K Buy
1,921
+783
+69% +$4.86K ﹤0.01% 5920
2024
Q4 		$7.57K Hold
1,138
– – ﹤0.01% 5988
2024
Q3 		$7.51K Buy
1,138
+166
+17% +$1.24K ﹤0.01% 5855
2024
Q2 		$9.17K Buy
+972
New +$12.5K ﹤0.01% 5767

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Wells Fargo's ENGN Position: Q1 2026 in Review

Wells Fargo increased its enGene Therapeutics (ENGN) stake by 11% in Q1 2026, buying an estimated $11.1K and bringing the position to 12,467 shares worth $84.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5188.

Wells Fargo first reported a position in ENGN in Q2 2024 and has held it in 8 quarters since. The position peaked at $122K in Q3 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Wells Fargo held 12,467 shares of enGene Therapeutics worth $84.9K as of Q1 2026.
  • Wells Fargo bought 1,250 enGene Therapeutics shares in Q1 2026, an estimated $11.1K.
  • enGene Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5188 holding.
  • Wells Fargo first reported a position in enGene Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Wells Fargo's enGene Therapeutics position peaked at $122K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.